About Herz-Jesu Krankenhaus
Clinical Trials at Herz-Jesu Krankenhaus
During the past decade, Herz-Jesu Krankenhaus conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Herz-Jesu Krankenhaus
According to Clinical.Site data, the most researched conditions in "Herz-Jesu Krankenhaus" are
"Arthrosis" (1 trials), "Avascular Necrosis" (1 trials), "Avascular Necrosis of the Femoral Head" (1 trials), "Congenital Hip Dysplasia" (1 trials) and "Inflammatory Arthritis" (1 trials). Many other conditions were trialed in "Herz-Jesu Krankenhaus" in a lesser frequency.
Clinical Trials Intervention Types at Herz-Jesu Krankenhaus
Most popular intervention types in "Herz-Jesu Krankenhaus" are "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "SMS femoral stem" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Herz-Jesu Krankenhaus
The vast majority of trials in "Herz-Jesu Krankenhaus" are
2 trials for "All" genders.
Clinical Trials Status at Herz-Jesu Krankenhaus
Currently, there are NaN active trials in "Herz-Jesu Krankenhaus".
undefined are not yet recruiting,
1 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Herz-Jesu Krankenhaus,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Herz-Jesu Krankenhaus, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".